PTSM: Pharmaceutical Technology Sourcing and Management, Sep 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
PTSM: Pharmaceutical Technology Sourcing and Management, Sep 5, 2012
APIs
Evaluating Market Opportunities in Orphan Drugs
By Patricia Van Arnum
Although serving niche areas, orphan drugs offer good market opportunities for pharmaceutical companies and their suppliers.
Supply Chain
Moving to Risk-Based Inspections
By Patricia Van Arnum
The Generic Drug User Fee Act seeks to improve and enhance regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.
Drug Delivery
Drug Delivery Insights: Injectable Drugs
By Patricia Van Arnum
A roundup of the latest developments for drug delivery of parenteral drugs.
Outsourcing
Gauging Biopharm Outsourcing
By Eric Langer
Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.
CSR and Sustainability Forum
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.
Using Microfluidic Chip Technology for Assessing Drug Quality
By Patricia Van Arnum
A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here